A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Tolvaptan in Healthy Korean Male Subjects Bipolar Disorder.

Trial Profile

A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Tolvaptan in Healthy Korean Male Subjects Bipolar Disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Korea Otsuka International Asia Arab Co
  • Most Recent Events

    • 29 Nov 2011 Results published in the Journal of Cardiovascular Pharmacology.
    • 12 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 12 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top